In the biopharmaceutical industry, the conventional “linear and sequential” clinical trial approach is still the norm; however, it is frequently beset by issues with patient selection, retention, and monitoring that are not up to par, leading to longer trial durations and higher trial failure rates. Artificial intelligence (AI) has the potential to reduce the duration of clinical trials significantly, expedite protocol design and study implementation, improve trial outcomes, and lower the cost of biopharmaceutical R&D. AI may also speed up clinical cycle times. Clinical trial mining, design and execution, and real-world experience analysis are all possible using AI. Major drug makers are utilizing AI to locate volunteers for clinical trials or to cut down on the number of subjects required for drug testing, which might speed up medication development and save millions of dollars. The clinical trial procedure may be enhanced by AI, but evidentiary requirements for a drug’s efficacy and safety won’t alter, according to regulators. This article discusses the application of AI, RWD, and RWE in clinical trials and how it is transforming the biopharma value chain, encompassing all pharmaceutical firms referred to as “biopharma companies” due to the inclusion of biologics in their development pipelines and within these biopharma firms, artificial intelligence (AI) is finding its way into drug research.
1 January 2026 in Brazilian Journal of Pharmaceutical Sciences
A significant advancement in contemporary healthcare is the introduction of biosimilars into the pharmaceutical sector. Because they are physiologically identical to reference biological products, biosimilars offer a more affordable option for the treatment of serious chronic illnesses such multiple sclerosis, diabetes, cancer, and autoimmune diseases. Biosimilars must exhibit similar efficacy, safety, and quality to the reference biologics despite differences in production methods. In the United States, regulatory frameworks like the Biologics Price Competition and Innovation Act (BPCIA) of 2009 have streamlined the biosimilar approval process, promoting competition and possibly lowering healthcare costs. Nevertheless, negotiating the patent landscape remains challenging due to the intricate “patent dance” litigation process and exclusivity periods for original biologics. Biosimilars also encounter competition from biobetters, improved biologics versions, and non-original biologics in less regulated markets.Recent technologies such as artificial intelligence (AI) and big data analytics are reshaping biosimilar development by enhancing clinical trial efficiency and product accuracy. Manufacturers are increasingly concentrating on biosimilars, driven by strategic partnerships, regulatory advancements, and the potential for substantial cost savings. Despite challenges like regulatory complexity and market competition, biosimilars are positioned to have a crucial role in widening patient access to essential therapies while fostering innovation in pharmaceutical sector.